Clinical Research Directory
Browse clinical research sites, groups, and studies.
Real-World Outcomes in Relapsed/Refractory Multiple Myeloma Patients Treated, or Eligible for Treatment, With Idecabtagene Vicleucel
Sponsor: Bristol-Myers Squibb
Summary
The purpose of this study is to describe demographic and disease characteristics, treatment patterns, and clinical outcomes in the real-world setting among participants in France with relapsed/refractory multiple myeloma (RRMM) who are eligible for treatment with, or have been treated with, idecabtagene vicleucel. This study will use both prospective and retrospective data from the DESCAR-T registry database.
Official title: ABE-DESCART Study: Characterization and Outcomes of Patients With Relapsed and Refractory Multiple Myeloma Eligible for Treatment or Treated With Abecma© (Idecabtagene Vicleucel) in Real World Setting in France. A Database Analysis Based on the DESCAR-T Registry
Key Details
Gender
All
Age Range
Any - Any
Study Type
OBSERVATIONAL
Enrollment
350
Start Date
2022-07-29
Completion Date
2027-12-31
Last Updated
2023-12-04
Healthy Volunteers
No
Conditions
Interventions
Idecabtagene vicleucel
According to approved product label in France
Not treated
Eligible for idecabtagene vicleucel treatment but not treated
Locations (1)
DESCAR-T Registry
Paris, France